Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.44
MKGAY's Cash to Debt is ranked higher than
53% of the 775 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.08 vs. MKGAY: 0.44 )
MKGAY' s 10-Year Cash to Debt Range
Min: 0.28   Max: No Debt
Current: 0.44

Equity to Asset 0.52
MKGAY's Equity to Asset is ranked higher than
60% of the 728 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.60 vs. MKGAY: 0.52 )
MKGAY' s 10-Year Equity to Asset Range
Min: 0.46   Max: 0.57
Current: 0.52

0.46
0.57
F-Score: 5
Z-Score: 1.30
M-Score: -2.86
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 14.52
MKGAY's Operating margin (%) is ranked higher than
83% of the 741 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.25 vs. MKGAY: 14.52 )
MKGAY' s 10-Year Operating margin (%) Range
Min: 6.69   Max: 19.54
Current: 14.52

6.69
19.54
Net-margin (%) 10.84
MKGAY's Net-margin (%) is ranked higher than
80% of the 741 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.16 vs. MKGAY: 10.84 )
MKGAY' s 10-Year Net-margin (%) Range
Min: 2.91   Max: 49.88
Current: 10.84

2.91
49.88
ROE (%) 10.86
MKGAY's ROE (%) is ranked higher than
83% of the 752 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.97 vs. MKGAY: 10.86 )
MKGAY' s 10-Year ROE (%) Range
Min: 3.96   Max: 40.81
Current: 10.86

3.96
40.81
ROA (%) 5.77
MKGAY's ROA (%) is ranked higher than
80% of the 777 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.87 vs. MKGAY: 5.77 )
MKGAY' s 10-Year ROA (%) Range
Min: 2.25   Max: 23.59
Current: 5.77

2.25
23.59
ROC (Joel Greenblatt) (%) 31.26
MKGAY's ROC (Joel Greenblatt) (%) is ranked higher than
88% of the 772 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.60 vs. MKGAY: 31.26 )
MKGAY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 12.99   Max: 43.04
Current: 31.26

12.99
43.04
Revenue Growth (%) 6.10
MKGAY's Revenue Growth (%) is ranked higher than
71% of the 659 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.60 vs. MKGAY: 6.10 )
MKGAY' s 10-Year Revenue Growth (%) Range
Min: -11   Max: 13
Current: 6.1

-11
13
EBITDA Growth (%) 9.10
MKGAY's EBITDA Growth (%) is ranked higher than
75% of the 618 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.60 vs. MKGAY: 9.10 )
MKGAY' s 10-Year EBITDA Growth (%) Range
Min: 1   Max: 13.2
Current: 9.1

1
13.2
EPS Growth (%) 24.10
MKGAY's EPS Growth (%) is ranked higher than
84% of the 597 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. MKGAY: 24.10 )
MKGAY' s 10-Year EPS Growth (%) Range
Min: -25.5   Max: 51.8
Current: 24.1

-25.5
51.8
» MKGAY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with MKGAY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 23.00
MKGAY's P/E(ttm) is ranked higher than
85% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 44.30 vs. MKGAY: 23.00 )
MKGAY' s 10-Year P/E(ttm) Range
Min: 17.23   Max: 261.35
Current: 23

17.23
261.35
P/B 0.80
MKGAY's P/B is ranked higher than
96% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.38 vs. MKGAY: 0.80 )
MKGAY' s 10-Year P/B Range
Min: 0.17   Max: 0.8
Current: 0.8

0.17
0.8
P/S 1.10
MKGAY's P/S is ranked higher than
90% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.70 vs. MKGAY: 1.10 )
MKGAY' s 10-Year P/S Range
Min: 0.9   Max: 7.96
Current: 1.1

0.9
7.96
PFCF 4.90
MKGAY's PFCF is ranked higher than
99% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. MKGAY: 4.90 )
MKGAY' s 10-Year PFCF Range
Min: 3.45   Max: 21.47
Current: 4.9

3.45
21.47
EV-to-EBIT 5.83
MKGAY's EV-to-EBIT is ranked higher than
99% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.72 vs. MKGAY: 5.83 )
MKGAY' s 10-Year EV-to-EBIT Range
Min: 4   Max: 114.2
Current: 5.83

4
114.2
PEG 1.70
MKGAY's PEG is ranked higher than
91% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. MKGAY: 1.70 )
MKGAY' s 10-Year PEG Range
Min: 1.05   Max: 2.83
Current: 1.7

1.05
2.83
Shiller P/E 37.70
MKGAY's Shiller P/E is ranked higher than
76% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 150.63 vs. MKGAY: 37.70 )
MKGAY' s 10-Year Shiller P/E Range
Min: 33.7   Max: 43.06
Current: 37.7

33.7
43.06
Current Ratio 1.20
MKGAY's Current Ratio is ranked lower than
51% of the 625 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.47 vs. MKGAY: 1.20 )
MKGAY' s 10-Year Current Ratio Range
Min: 1.2   Max: 3.09
Current: 1.2

1.2
3.09
Quick Ratio 0.89
MKGAY's Quick Ratio is ranked lower than
52% of the 625 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.81 vs. MKGAY: 0.89 )
MKGAY' s 10-Year Quick Ratio Range
Min: 0.89   Max: 2.62
Current: 0.89

0.89
2.62

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.00
MKGAY's Dividend Yield is ranked lower than
53% of the 458 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.37 vs. MKGAY: 1.00 )
MKGAY' s 10-Year Dividend Yield Range
Min: 1.07   Max: 4.79
Current: 1

1.07
4.79
Dividend Payout 0.23
MKGAY's Dividend Payout is ranked higher than
88% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. MKGAY: 0.23 )
MKGAY' s 10-Year Dividend Payout Range
Min: 0.88   Max: 5.77
Current: 0.23

0.88
5.77
Dividend growth (3y) -100.00
MKGAY's Dividend growth (3y) is ranked higher than
56% of the 329 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -0.10 vs. MKGAY: -100.00 )
MKGAY' s 10-Year Dividend growth (3y) Range
Min: 0   Max: -28.3
Current: -100

Yield on cost (5-Year) 1.00
MKGAY's Yield on cost (5-Year) is ranked lower than
54% of the 466 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.37 vs. MKGAY: 1.00 )
MKGAY' s 10-Year Yield on cost (5-Year) Range
Min: 1.07   Max: 4.79
Current: 1

1.07
4.79

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.20
MKGAY's Price/DCF (Projected) is ranked higher than
92% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.06 vs. MKGAY: 1.20 )
MKGAY' s 10-Year Price/DCF (Projected) Range
Min: 0.16   Max: 1.24
Current: 1.2

0.16
1.24
Price/Median PS Value 1.00
MKGAY's Price/Median PS Value is ranked higher than
94% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.26 vs. MKGAY: 1.00 )
MKGAY' s 10-Year Price/Median PS Value Range
Min: 0.56   Max: 4.69
Current: 1

0.56
4.69
Price/Peter Lynch Fair Value 1.60
MKGAY's Price/Peter Lynch Fair Value is ranked higher than
96% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. MKGAY: 1.60 )
MKGAY' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.94   Max: 2.74
Current: 1.6

0.94
2.74
Earnings Yield (Greenblatt) 17.20
MKGAY's Earnings Yield (Greenblatt) is ranked higher than
95% of the 641 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.70 vs. MKGAY: 17.20 )
MKGAY' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.9   Max: 25.2
Current: 17.2

0.9
25.2
Forward Rate of Return (Yacktman) 28.71
MKGAY's Forward Rate of Return (Yacktman) is ranked higher than
94% of the 633 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.43 vs. MKGAY: 28.71 )
MKGAY' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -3.3   Max: 30.9
Current: 28.71

-3.3
30.9

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:LSE:0NZZ, TKPYY, TEVA, AGN, FRX » details
Traded in other countries:MRK.Germany, 0O14.country
Merck KGaA is a pharmaceutical and chemical company. It operates as a manufacturer of standard and specialty chemicals for the laboratory and industry. he Company researches drugs in the areas oncology and neurodegenerative as well as autoimmune and inflammatory diseases. The Company operate its businesses in four divisions: Merck Serono (prescription medicines), Consumer Health (over-the-counter pharmaceuticals), Performance Materials (high-tech chemicals) and Merck Millipore (products for pharmaceutical research and biotechnology).:. Within the Merck Serono division, the Company researches on therapeutic areas and prescription drugs of chemical and biotechnological origin. The Consumer Health division comprises the over-the-counter products for preventive health care and self-treatment of minor ailments. The Merck Serono and Consumer Health divisions form together the Company's Pharmaceutical business sector. The Merck Millipore division comprises the activities of the Millipore Corporation. The Performance Materials division consists mainly of the Liquid Crystals and Pigments & Cosmetics business units. The Company also markets cardiovascular, fertility, endocrinology, and over-the-counter products as well as products for flat screens and the pharmaceutical, food, cosmetics, packaging, and coatings.
» More Articles for OTCPK:MKGAY

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Oncothyreon (ONTY) Slumps, Tecemotide Fails Phase I/II Study Aug 20 2014
Merck Reports Organic Growth in all Four Businesses in Second Quarter Aug 13 2014
Merck Serono Awards Innovation Cup and € 10,000 to Team Oncology for their Innovative Approach to... Aug 07 2014
Merck Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell... Jul 29 2014
Merck KGaA CEO Karl-Ludwig Kley and German Federal Economics Minister Sigmar Gabriel Commission... Jul 28 2014
Merck CEO Karl-Ludwig Kley and German Federal Economics Minister Sigmar Gabriel Commission... Jul 28 2014
Merck Serono Announces Collaboration with San Raffaele University & Research Hospital for Research... Jul 24 2014
Merck Strengthens Commitment to Chinese Growth Market Jul 23 2014
Merck KGaA Strengthens Commitment to Chinese Growth Market Jul 23 2014
Merck Completes Squeeze-Out of AZ Electronic Materials Jul 16 2014
Merck Serono Announces Global Grants Program to Fund Scientific Innovation Jul 16 2014
Merck Serono Appoints Luciano Rossetti as Global Head of R&D Jul 16 2014
Merck KGaA’s Biopharmaceutical Division Appoints Luciano Rossetti as Global Head of R&D Jul 14 2014
Roche unit, Merck KGaA to develop companion test for cancer treatment Jul 10 2014
EMD Serono to Release New Pipeline Data at ASCO 2014 from Early-Stage Investigational Compounds in... May 29 2014
Bayer to buy Merck consumer business for $14.2B May 06 2014
Bayer to buy Merck consumer business for $14.2B May 06 2014
Germany's Bayer to buy Merck consumer business May 06 2014
Germany's Bayer to buy Merck consumer business May 06 2014
Merck Wins Chinese Approval for AZ Electronics Takeover May 01 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK